Pharmacyte Biotech Inc (OTCMKTS:PMCB) has decided to discuss some of its major milestones right before the phase 2b clinical trial in pancreatic cancer begins. Pharmacyte is one of the leading names in biotech firms focusing on the development of diabetes and cancer treatments with the help of its flagship live-cell encapsulation technology named Cell-in-a-Box.
In this treatment, genetically modified live cells combined with low doses of ifosfamide are put together with microcapsules. Ifosfamide is a sought after chemotherapy drug used by health care experts all around the globe.
Milestones Discussed By Pharmacyte Biotech
Some of the major milestones discussed by the company ahead of initiation of the trial are as follows-
Clinical Protocol: A protocol will soon be prepared by Pharmacyte’s Contract Research Organization under the guidance of company’s oncologists. This protocol can be seen as a recipe of how the clinical trial in pancreatic cancer will be conducted by the company.
IND Team: It will also form a team to come up with the IND and get it reviewed before the final submission to authorities. This team will comprise of a host of key resources who will use their expertise and knowledge to come up with a perfect solution.
Other milestones that Pharmacyte discussed include finalizing trial design, chemistry, control and manufacturing information, Pre-IND meeting, etc.
Stellar Biotechnologies Inc (OTCMKTS:SBOTD) gave an update to all the shareholders concerning its listing on NASDAQ marketplace. As per the reports, the company has decided to schedule a shareholder meeting on October 29, 2015, to discuss a few important corporate governance requirements. Stellar hopes to get an uninterrupted approval from shareholders to carry out further proceedings in a hassle-free way.
With the help of continuous hard work and persistence, USANA Health Sciences, Inc. (NYSE:USNA) has managed to earn a place among 50 top-notch companies in Utah state. The Utah Business Fast 50 List comprises of all the companies that register the highest growth in any given year. It’s the 8th straight occasion when USNA has grabbed a place in this list.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of USmarketsDaily.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: